« Back to Pipeline

COVID-19 Treatment: COVIDTRAP (ACE2 Receptor Decoy – STI 4398)

COVIDTRAP has demonstrated antiviral efficacy in in vitro cell culture models of coronavirus infection. COVIDTRAP is being developed to treat COVID-19 without the risk of Antibody Dependent Enhancement (ADE) of infection. The Fc portion of the COVIDTRAP molecule is engineered to abrogate interactions with Fc receptors of immune cells.